Eli Lilly and Co（LLY）の株式分析LLYEli Lilly and Co

Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Eli Lilly is a good buy right now due to its current price of $1179.27, a strong year-to-date change of +9.16%, and a forward P/E ratio of 24.39, which suggests growth potential. The main risk is the high debt to equity ratio of 162.07%, indicating potential financial strain.

22 analysts cover LLY: 13 rate it Buy, 8 Hold and 1 Sell. The average price target is 1,192.